AAPL   318.88 (+0.20%)
MSFT   181.97 (+0.31%)
FB   224.87 (-0.26%)
CGC   17.59 (-18.57%)
BABA   199.13 (-0.47%)
GE   6.54 (-3.68%)
TSLA   821.23 (+1.91%)
T   30.55 (-1.67%)
GILD   75.02 (-0.32%)
DIS   115.35 (-1.53%)
NFLX   413.50 (+0.01%)
BA   144.10 (-3.82%)
AAPL   318.88 (+0.20%)
MSFT   181.97 (+0.31%)
FB   224.87 (-0.26%)
CGC   17.59 (-18.57%)
BABA   199.13 (-0.47%)
GE   6.54 (-3.68%)
TSLA   821.23 (+1.91%)
T   30.55 (-1.67%)
GILD   75.02 (-0.32%)
DIS   115.35 (-1.53%)
NFLX   413.50 (+0.01%)
BA   144.10 (-3.82%)
AAPL   318.88 (+0.20%)
MSFT   181.97 (+0.31%)
FB   224.87 (-0.26%)
CGC   17.59 (-18.57%)
BABA   199.13 (-0.47%)
GE   6.54 (-3.68%)
TSLA   821.23 (+1.91%)
T   30.55 (-1.67%)
GILD   75.02 (-0.32%)
DIS   115.35 (-1.53%)
NFLX   413.50 (+0.01%)
BA   144.10 (-3.82%)
AAPL   318.88 (+0.20%)
MSFT   181.97 (+0.31%)
FB   224.87 (-0.26%)
CGC   17.59 (-18.57%)
BABA   199.13 (-0.47%)
GE   6.54 (-3.68%)
TSLA   821.23 (+1.91%)
T   30.55 (-1.67%)
GILD   75.02 (-0.32%)
DIS   115.35 (-1.53%)
NFLX   413.50 (+0.01%)
BA   144.10 (-3.82%)
Log in

ASX:NEUNeuren Pharmaceuticals Stock Price, Forecast & News

A$1.72
-0.02 (-1.15 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$1.66
Now: A$1.72
A$1.73
50-Day Range
A$1.07
MA: A$1.57
A$1.77
52-Week Range
A$0.97
Now: A$1.72
A$3.04
Volume57,935 shs
Average VolumeN/A
Market Capitalization$176.59 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Neuren Pharmaceuticals Limited, a biopharmaceutical company, engages in the development of drugs for the treatment of chronic neurodevelopmental and neurodegenerative disorders, and acute traumatic brain injury. Its lead product is trofinetide, which has completed Phase II clinical trials for the treatment of Rett syndrome; is in Phase II clinical trials for the treatment of Fragile X syndrome; and conducted Phase II clinical trials for the treatment moderate to severe traumatic brain injury. The company also develops NNZ-2591 that is in preclinical development for the treatment of Phelan-McDermid syndrome. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Camberwell, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.00 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 9092 0480

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$495,000.00
Cash FlowA$0.14 per share
Book ValueA$0.14 per share

Profitability

Miscellaneous

Employees8
Market Cap$176.59 million
Next Earnings DateN/A
OptionableOptionable

Receive NEU News and Ratings via Email

Sign-up to receive the latest news and ratings for NEU and its competitors with MarketBeat's FREE daily newsletter.

Neuren Pharmaceuticals (ASX:NEU) Frequently Asked Questions

How has Neuren Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Neuren Pharmaceuticals' stock was trading at A$1.68 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NEU stock has increased by 2.5% and is now trading at A$1.72. View which stocks have been most impacted by Coronavirus.

How were Neuren Pharmaceuticals' earnings last quarter?

Neuren Pharmaceuticals Ltd (ASX:NEU) issued its earnings results on Wednesday, February, 27th. The company reported $0.03 EPS for the quarter. View Neuren Pharmaceuticals' earnings history.

Has Neuren Pharmaceuticals been receiving favorable news coverage?

Headlines about NEU stock have trended positive this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Neuren Pharmaceuticals earned a news sentiment score of 2.7 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an impact on the stock's share price in the near term. View the latest news aboutNeuren Pharmaceuticals.

Who are some of Neuren Pharmaceuticals' key competitors?

What other stocks do shareholders of Neuren Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuren Pharmaceuticals investors own include Macquarie Group (MQG), Magellan Financial Group (MFG), Medlab Clinical (MDC), FBR (FBR), Evolve Education Group (EVO), Dacian Gold (DCN), CCP Technologies (CT1), Bingo Industries (BIN), Afterpay Touch Group (APT) and Alkane Resources (ALK).

Who are Neuren Pharmaceuticals' key executives?

Neuren Pharmaceuticals' management team includes the following people:
  • Dr. Richard Spencer Treagus BScMed, MBChB, MPharmMed, MBA, Exec. Chairman
  • Mr. Lawrence Glass, Chief Science Officer
  • Mr. Jonathan Charles Pilcher, CFO & Company Sec.

What is Neuren Pharmaceuticals' stock symbol?

Neuren Pharmaceuticals trades on the ASX under the ticker symbol "NEU."

What is Neuren Pharmaceuticals' stock price today?

One share of NEU stock can currently be purchased for approximately A$1.72.

How big of a company is Neuren Pharmaceuticals?

Neuren Pharmaceuticals has a market capitalization of $176.59 million and generates $495,000.00 in revenue each year. Neuren Pharmaceuticals employs 8 workers across the globe.

What is Neuren Pharmaceuticals' official website?

The official website for Neuren Pharmaceuticals is www.neurenpharma.com.

How can I contact Neuren Pharmaceuticals?

The company can be reached via phone at 61 3 9092 0480.

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.